Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial is a research paper published in PLoS Medicine (2024). On theSindex it has a DataRank of 0.439. It has been cited 9 times, with 7 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.345
From this paper's citation signal
Citation Network Contribution
0.0935
From 5 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 7 citers.
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: AI068614
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: AI068635
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: AI068618
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: AI069501
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: P30 AI064518
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: UM1 AI069453
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: HHSN272201600012C
Bill and Melinda Gates Foundation
Grant: OPP1017604
NIAID NIH HHS
Grant: UM1 AI068635
NIAID NIH HHS
Grant: U01 AI068614
NIAID NIH HHS
Grant: U01 AI068635
NIAID NIH HHS
Grant: U01 AI069501
NIAID NIH HHS
Grant: UM1 AI069501
NIAID NIH HHS
Grant: U01 AI068618
NIAID NIH HHS
Grant: UM1 AI069469
NIAID NIH HHS
Grant: U01 AI069436
NIAID NIH HHS
Grant: UM1 AI154463
NIAID NIH HHS
Grant: UM1 AI068614
NIAID NIH HHS
Grant: UM1 AI068618
NIAID NIH HHS
Grant: UM1 AI069436
National Institutes of Health
Grant: 3UM1AI068614-15S2
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
National Institutes of Health
Grant: 5P30AI064518-17
Centers for AIDS Research (CFAR)
National Institutes of Health
Grant: 5UM1AI069501-18
Case Clinical Trials Unit
National Institutes of Health
Grant: 3UM1AI068618-16S1
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
National Institutes of Health
Grant: 4UM1AI069453-07
Soweto Clinical Trials Unit
National Institutes of Health
Grant: 3UM1AI068635-17S4
CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.
FWCI
2.09
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals